AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03046563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure and Abdominal Massage
Description: Pressing the Hegu (LI 4), Zusanli (ST 36) , Tianshu(ST 25) and abdominal massage for eight minutes
Study NCT03046563 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Pressing the Sham points
Description: Pressing the sham points for eight minutes
Study NCT04443894 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PECS block
Description: PECS block is performed at the side of surgery (II) before incision with ropivacaine 0,375%.(30 ml). General anesthesia is induced and maintained with midazolam, fentanyl, propofol and rocuronium. Pain is assessed postoperatively according to protocol (24 hours and after 3 months).
Study NCT04443894 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: local infiltration
Description: local infiltration of the surgical wound before incision with πwith ropivacaine 0,375%.(30 ml). General anesthesia is induced and maintained with midazolam, fentanyl, propofol and rocuronium. Pain is assessed postoperatively according to protocol (24 hours and after 3 months).
Study NCT01964729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: The participants will be randomized into placebo-sham or rTMS or treatment groups for 10 consecutive sessions, at 10 Hz frequency.
Study NCT01964729 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Sham Comparator: For the placebo-controlled condition, we will use the same TMS equipment coupled with a placebo coil that produces the same active sound produced by the active coil.
Study NCT00083304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efaproxiral
Description: 75 mg/kg, administered over 30 minutes via a central venous access device (CVAD).~Administered 30 minutes prior to the start of whole brain radiation therapy (WBRT) on each WBRT treatment day for 10 days.
Study NCT00083304 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole Brain Radiation Therapy (WBRT)
Description: 3.0 Gy per day for 10 days (30.0 Gy total) of WBRT.
Study NCT00083304 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole Brain Radiation Therapy (WBRT)
Description: 3.0 Gy per day for 10 days (30.0 Gy total) of WBRT.
Study NCT00052481 — intervention group
Intervention type: PROCEDURE
Intervention: quality-of-life assessment
Study NCT02920372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPOETIN ALFA
Study NCT01257087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: All patients will be prescribed insulin glargine once a day. The dose of the insulin will be adjusted to achieve fasting capillary glucose levels between 5-7 in the intensive group and 7-9 mmol/l in the control group.
Study NCT00083304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplemental Oxygen
Description: 4 L/minute by nasal cannula.~Administered at least 35 minutes prior to WBRT, during WBRT and until 15 minutes after completion of WBRT on all WBRT treatment days.
Study NCT00083304 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supplemental Oxygen
Description: 4 L/minute by nasal cannula.~Administered at least 35 minutes prior to WBRT, during WBRT and until 15 minutes after completion of WBRT on all WBRT treatment days.
Study NCT04569617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training - UL endurance protocol
Description: UL endurance protocol - 2 series of 20 repetitions, elbow flexion at 40% of the maximum test force of 1 maximum repetition, (recovery 1 minutes between sets).
Study NCT01257087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: All patients will be prescribed insulin glargine once a day. The dose of the insulin will be adjusted to achieve fasting capillary glucose levels between 5-7 in the intensive group and 7-9 mmol/l in the control group.
Study NCT02158403 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Management Recommendations for reducing pump thrombosis
Description: Clinical Management Recommendations for reducing pump thrombosis
Study NCT04575116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis free acid tablet
Description: 12.2 mg tafamidis free acid tablet
Study NCT04575116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis meglumine capsule
Description: 20 mg tafamidis meglumine soft gelatin capsule
Study NCT04569617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training - UL strength protocol
Description: UL strength protocol - 2 series of 8 repetitions, elbow flexion at 80% of the maximum test force of 1 maximum repetition, (recovery 1 minutes between sets).
Study NCT02575937 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low glycemic diet
Description: nutrition education-based low glycemic diet intervention
Study NCT04569617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training - LL endurance protocol
Description: LL endurance protocol - 2 series of 20 repetitions, elbow flexion at 40% of the maximum test strength of 1 maximum repetition, (recovery 1 minutes between sets).
Study NCT04569617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training - LL strength protocol
Description: LL strength protocol - 2 series of 8 repetitions, knee extension at 80% of the maximum test force of 1 maximum repetition, (recovery 1 minutes between sets).
Study NCT01813968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning
Study NCT03859804 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard transrectal 12 core biopsy
Description: TRUS-guided SPB was performed by obtaining 12 core samples in each patient. 6 cores from left and right. the cores labeled as, apex, mid, base, apex far lateral, mid far lateral and base far lateral
Study NCT03859804 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI- US fusion prostate biopsy (FPB)
Description: FPB was performed by obtaining 10-12 core samples in each patient, followed by the acquisition of 2-4 core samples for each suspected lesion detected on MpMRI (combined biopsy)
Study NCT04300881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: Following intravitreal ocriplasmin therapy
Study NCT04513405 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood sampling
Description: a peripheral venous blood sample will be analyzed to measure the levels of estrone and estradiol.~The sample of the blood sample will be deposited in the red cap tube with a polymeric gel.
Study NCT01337232 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Complex sentence treatment protocol
Description: Treatment: listening, speaking, reading, and writing activities that teach three types of complex sentences. Individual sessions are 40 minutes in length, delivered by or under the supervision of a certified, trained speech-language pathologist.
Study NCT01337232 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Complex sentence treatment protocol
Description: Treatment: listening, speaking, reading, and writing activities that teach three types of complex sentences. Individual sessions are 40 minutes in length, delivered by or under the supervision of a certified, trained speech-language pathologist.
Study NCT04315909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRP-Fibrin Glue
Description: Platelet-Rich Plasma-Fibrin Glue
Study NCT02578030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP465 12.5mg
Study NCT04513405 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Shave Biopsy
Description: in the tissues, of the related estrogenic receptors, estrogen α receptors, estrogen β receptors (ER- α, ER-β) and G protein-coupled estrogen receptor 1 (GPER) correlates with the functional status of these receptors
Study NCT03183960 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentor
Description: Traditional rehabilitation.
Study NCT03183960 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mentor
Description: Traditional rehabilitation.
Study NCT04546867 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Sonographic based visualization of a pancreatic stent
Description: As described above. All patients start with an ultasound-based approach to visualize pancreatic stents position. Depending on the findings, x-ray will be performed if no stent is visualized in the pancreatic duct or an esophagogastroduodenoscopy will be performed to remove the pancreatic stent and confirm sonographic findings if the pancreatic stent is displayed in situ.
Study NCT00674375 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic risk alerts
Description: Electronic risk alerts within the electronic medical record system will automatically calculate a patient's Framingham Risk Score during office visits for chest pain. These alerts will recommend electrocardiogram performance and aspirin therapy for patients with Framingham Risk Score at least 10%, and will recommend against exercise stress testing for patients with a Framingham Risk Score less than 10%.
Study NCT02805062 — intervention group
Intervention type: PROCEDURE
Intervention: Digital Pleural Manometry
Description: Measurement of intra-pleural pressure and the removal of pleural fluid.
Study NCT02805062 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging
Description: Subject lies a long tunnel shaped scanner and images are recorded.
Study NCT01095666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 5 mg, Once daily, 24 weeks
Study NCT01095666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 10 mg, Once daily, 24 weeks
Study NCT01095666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablets, Oral, 1500-3000 mg, Twice daily, 24 weeks
Study NCT01095666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin Placebo
Description: Tablets, Oral, 0 mg, Once daily, 24 weeks
Study NCT02578030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP465 25mg
Study NCT01095666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Tablets, Oral, 15-45 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks
Study NCT01687244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSTILADRIN
Description: The INSTILADRIN components will be mixed with a diluent. The total dose will be given as a single, one-hour intravesical administration which may, depending on clinical response, be repeated every 3 months up to a maximum of 4 instillations.
Study NCT04315909 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E and C
Description: Vitamin E and vitamin C
Study NCT04315909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT01105728 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic resection
Description: Endoscopic resection of the gastric subepithelial mass
Study NCT04367428 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Administration of probiotics
Description: Patients will receive the previously mentioned combination of probiotics before and after surgery
Study NCT03798405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive Analgesic Inpatient Narcotic-Sparing
Description: Medications suggested to the physician with enhanced ease of ordering.
Study NCT04356391 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Connective Tissue Graft Technique
Description: For the sites receiving the control technique (Connective Tissue Graft), the technique described by Langer B. and Langer L. will be started with a sulcular incision followed by a partial thickness flap. A CTG is then harvested according to the technique described by Bruno, the first incision is perpendicular to the 2nd premolar and 1st molar and is 2-3mm apical to their gingival margin as wide as the recipient site, followed by a second incision parallel to the for mentioned teeth, 1-2mm apical to the first incision, then the CTG is raised by periosteal elevator and released from apical and lateral attachments by sharp incision when needed. The graft is then prepared to have a homogenous thickness of 1.5-2mm. The donor CTG is stabilized to the underlying connective tissue interproximally using 4-0 Vicryl sutures. The recipient flap is repositioned coronally, to cover as much as possible of the graft with no tension, 2mm coronal to the CEJ, then sutured with 4-0 Vicryl sutures.
Study NCT03383614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSF emodepside (BAY 44-4400) or matching placebo
Description: Emodepside administered as an LSF oral solution (1mg/mL)
Study NCT02447640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX48621
Description: ADX4862, an investigational compound, is a potent, selective, negative allosteric modulator of the metabotropic glutamate receptor 5 (mGlu5 NAM).
Study NCT02447640 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]FPEB
Description: radiotracer used for PET scanning
Study NCT03623022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clinical Center Reference Endotoxin (CCRE)
Description: subjects will undergo an exposure to inhaled endotoxin through a nebulizer for approximately 10 minutes.
Study NCT03623022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: subjects will undergo an exposure to inhaled normal saline through a nebulizer for approximately 10 minutes
Study NCT05146934 — intervention group
Intervention type: RADIATION
Intervention: high resolution CT
Description: Ground glass，honeycomb，reticulation, consolidation
Study NCT01459887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP combined with CMAB304
Description: Patients treated with CHOP-304 undergo 1 cycle every 3 weeks, received CMAB304 at a dose of 375 mg/m2 on day 1 and CHOP on day 2 of each of the 6 cycles.
Study NCT01459887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP, CMAB304
Description: First standard CHOP, then sequential CMAB304 in patients who reached a complete response or undocumented complete response at the end of treatment of 6 cycles.
Study NCT02293590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Certolizumab Pegol
Study NCT02293590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Study NCT03595449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine jelly
Description: lidocaine 2% jelly applied during Mohs surgery
Study NCT03595449 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Surgilube
Description: surgilube (placebo) applied during Mohs surgery
Study NCT02754661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COLON Capsule endoscopy
Study NCT02754661 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomographic Colonography
Study NCT03253133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Dose levels of Oxaliplatin:~4 dose levels of Oxaliplatin (85, 100, 130 and 160 mg/m²) are planned. 1 dose level is planned (-1 : 70 mg/m²) if DLT is reached at level 1~Table 1: Dose levels~Dose Level Dose (mg/m²) Number of patients DL -1 70 mg 3-6 DL 1 \* 85 mg 3-6 DL 2 100 mg 3-6 DL 3 130 mg 3-6 DL 4 160 mg 3-6~\* Start level
Study NCT03253133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV5FU or Folfiri
Description: Association of chemotherapy by LV5FU or Folfiri according pratician choice
Study NCT03253133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Oxycodone
Study NCT00201760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 IV over 30 minutes on Days 1 and 8.
Study NCT00201760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m2 IV over 30 minutes on Days 1 and 8.
Study NCT00201760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 2 mg/kg IV on days 1, 8 and 15. If Trastuzumab has not been administered within the 3 weeks before starting this treatment, the first dose of Trastuzumab given on Cycle 1, Day 1 will be 4 mg/kg followed by 2 mg/kg weekly.
Study NCT00201760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 2 mg/kg IV on days 1, 8 and 15. If Trastuzumab has not been administered within the 3 weeks before starting this treatment, the first dose of Trastuzumab given on Cycle 1, Day 1 will be 4 mg/kg followed by 2 mg/kg weekly.
Study NCT00201760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 30 mg/m2 IV on Day 1 and Day 8.
Study NCT00500812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cethrin
Study NCT03964506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Description: Reduced intensity conditioning Fludarabine and Melphalan with Hyperbaric Oxygen and Allogeneic Hematopoietic Stem Cell Transplant
Study NCT01871272 — intervention group
Intervention type: PROCEDURE
Intervention: Arthroscopic Meniscus Surgery
Description: Surgery to the meniscus - resection or repair.
Study NCT03032250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Intervention
Description: Attend interventionist sessions
Study NCT03032250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Watch video
Description: Watch video on a DVD
Study NCT01265810 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: supersaturated calcium-phosphate
Description: 4 times daily, 2 minutes rinse with 30 ml solution during active rinse period (14 days)
Study NCT01265810 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: sodium chloride 0.9 %
Description: 4 times daily, 2 minutes rinse with 30 ml solution during active rinse period (14 days)
Study NCT03032250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Module completion of the Prepare to Care kit
Description: Complete modules of the Prepare to Care kit
Study NCT03032250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03032250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT03032250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Salivary cortisol collection
Description: Obtained at three times a day (at awakening, 30 minutes post awakening and bedtime) for two consecutive days for eligible caregivers in both groups. Samples collected by placing a cotton ball under the tongue for approximately 1-2 minutes which is subsequently stored in a plastic tube and refrigerated.
Study NCT00014170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given orally
Study NCT00014170 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00014170 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00014170 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT00014170 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01614912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM-13496
Description: 40 or 80 mg once daily orally
Study NCT00254163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Study NCT00254163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Study NCT00254163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT00254163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Study NCT00254163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study NCT00254163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Study NCT04356391 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pinhole Surgical Technique
Description: For the sites receiving the test technique (Chao Pinhole Surgical Technique) the surgery starts with a small pinhole opening in the alveolar mucosa apical to the mucogingival junction of the affected tooth, the flap is then undermined using special instruments to create a full thickness pouch, followed by extending the pouch horizontally and coronally to undermined the adjacent papilla without incising it and free the flap for its coronal displacement. Then multiple 2x12mm strips of collagen resorbable membrane material (Bio-Gide, Geistlich Pharma AG) are packed under the papilla to secure the flap in a coronal direction. Gentle pressure is applied for 5 minutes to minimize the thickness of the blood clot after each of the procedures. The patients are advised to brush all teeth and sites except the buccal surfaces of the operated-on teeth, which are to be cleaned with 0.12% Chlorhexidine mouth rinse.
Study NCT02256020 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Original lifestyle
Description: Control group with 3 times of watching 50-minute television a week for 6 months.